[{"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-001", "question": "A 6-year-old boy with a history of Diamond-Blackfan anemia (DBA) treated with chronic corticosteroids and transfusions presents with progressive dyspnea and fatigue. Echocardiography reveals a restrictive cardiomyopathy with severe biventricular diastolic dysfunction and moderate pulmonary hypertension. Genetic testing confirms a pathogenic variant in RPS19. Which of the following is the most appropriate next step in management?", "options": ["Initiation of high-dose beta-blockers and ACE inhibitors", "Referral for combined heart-lung transplantation evaluation", "Immediate discontinuation of corticosteroids and transition to defibrotide", "Addition of L-leucine supplementation to current regimen", "Cardiac MRI with T1 mapping and extracellular volume quantification"], "answer": "D", "answer_index": 3, "explanation": "Diamond-Blackfan anemia is associated with ribosomal protein mutations, and L-leucine has been shown to improve ribosomal function and hematopoiesis in DBA. In patients with DBA-associated cardiomyopathy, addressing the underlying ribosomal dysfunction with leucine supplementation may improve cardiac function, whereas conventional heart failure therapies are less effective for this specific pathophysiology. Beta-blockers/ACE inhibitors would be insufficient, transplantation is premature without addressing the underlying metabolic defect, defibrotide is for hepatic veno-occlusive disease, and advanced imaging would not change management.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "E", "model_outputs": "The clinical presentation of a 6-year-old boy with Diamond-Blackfan anemia (DBA) who has been transfusion-dependent involves progressive heart failure characterized by restrictive cardiomyopathy. The history of chronic transfusions is the key risk factor for secondary hemochromatosis (iron overload).\n\n1.  Pathophysiology: Chronic red blood cell transfusions inevitably lead to iron overload. Without adequate chelation, excess iron deposits in the liver, endocrine glands, and myocardium. myocardial siderosis typically manifests first as diastolic dysfunction and restrictive cariomyopathy, which can progress to dilated cardiomyopathy and systolic failure if untreated. The echocardiogram findings (restrictive cardiomyopathy, diastolic dysfunction) are classic for cardiac iron overload.\n2.  Management: Iron-induced cardiomyopathy is potentially reversible with aggressive iron chelation therapy (e.g., continuous IV deferoxamine, often combined with oral chelators). It is considered a medical emergency.\n3.  Diagnostic Steps: The gold standard for diagnosing and quantifying myocardial iron overload is Cardiovascular Magnetic Resonance (CMR), specifically measuring T2* relaxation times. T1 mapping is another CMR technique; native T1 times are significantly shortened in the presence of myocardial iron (similar to T2* but with potentially higher sensitivity and reproducibility in some contexts). Calculating Extracellular Volume (ECV) helps assess myocardial fibrosis. Distinguishing between active iron loading (treatable with chelation) and extensive fibrosis (irreversilbe) is crucial for prognosis and management.\n4.  Evaluating Options:\n    *   A: High-dose beta-blockers and ACE inhibitors are standard for dilated cardiomyopathy with reduced ejection fraction but must be used with extreme caution in restrictive cardiomyopathy, where cardiac output is often heart-rate dependent. Furthermore, this does not address the underlying etiology (iron).\n    *   B: Heart-lung transplantation is a consideration for end-stage, irreversible heart failure and fixed pulmonary hypertension. However, given that iron cardiomyopathy is often reversible, attempting intensive chelation is the priority before considering transplant.\n    *   C: Defibrotide is used for hepatic veno-occlusive disease (VOD), not for this condition. Discontinuing steroids abruptly is dangerous.\n    *   D: L-leucine is an investigational/off-label therapy used to improve erythropoiesis in DBA (treating the anemia), but it does not treat acute cardiac decompensation.\n    *   E: Cardiac MRI is the requisite diagnostic tool to confirm myocardial iron overload and assess the extent of fibrosis (via T1 mapping/ECV) to guide the decision between intensive chelation and transplant evaluation.\n\nTherefore, the most appropriate next step is to characterize the myocardium to confirm the diagnosis of iron overload and assess tissue viability.\n\nThe answer is (E)"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-002", "question": "A 34-year-old pregnant woman at 32 weeks gestation presents with acute-onset severe hypertension (200/120 mmHg), headache, and visual disturbances. Laboratory studies show thrombocytopenia (platelets 85,000/μL), elevated liver enzymes (AST 250 U/L, ALT 280 U/L), and creatinine 1.8 mg/dL. Magnesium sulfate is initiated. Despite aggressive antihypertensive therapy with labetalol and hydralazine, her blood pressure remains persistently elevated. Which of the following is the most appropriate next pharmacologic intervention?", "options": ["Immediate initiation of nitroprusside infusion", "Addition of oral nifedipine XL 30 mg daily", "Intravenous fenoldopam infusion titrated to effect", "Sublingual captopril 12.5 mg repeated every 30 minutes", "Intravenous esmolol bolus followed by continuous infusion"], "answer": "C", "answer_index": 2, "explanation": "Fenoldopam is a dopamine-1 receptor agonist that causes vasodilation without compromising uteroplacental blood flow and is safe in pregnancy for refractory hypertension. Nitroprusside is contraindicated due to risk of cyanide toxicity to the fetus. Nifedipine XL has slow onset and is inadequate for acute control. ACE inhibitors like captopril are contraindicated in pregnancy due to fetal renal toxicity. Esmolol may cause fetal bradycardia and is less ideal than fenoldopam for pregnancy-associated hypertensive emergencies.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The clinical presentation describes a pregnant woman at 32 weeks gestation with severe preeclampsia/HELLP syndrome (thrombocytopenia, elevated liver enzymes, renal insufficiency) and severe hypertension (200/120 mmHg) refractory to first-line agents (magnesium sulfate, labetalol, and hydralazine). This is a hypertensive emergency with imminent risk of maternal stroke, placental abruption, and fetal demise.\n\nAccording to ACOG guidelines (Practice Bulletin No. 222) and standard obstetric critical care protocols:\n1.  First-line agents for acute-onset severe hypertension in pregnancy are IV labetalol, IV hydralazine, or oral *immediate-release* nifedipine. The patient has already received labetalol and hydralazine without success.\n2.  Second-line/Rescue agents: When hypertension is refractory to first-line agents, potent intravenous vasodilators are indicated. The two most commonly cited agents for this scenario are nicardipine or sodium nitroprusside.\n    *   Sodium nitroprusside (Option A) is a potent arterial and venous vasodilator with rapid onset. It is reserved for extreme emergencies (rapid control of hypertensive crisis) where other agents have failed. Although there is a risk of fetal cyanide toxicity and maternal thiocyanate toxicity (particularly with renal insufficiency or prolonged use >4 hours), it is the appropriate choice for immediate life-saving blood pressure reduction in this refractory setting to prevent maternal intracranial hemorrhage.\n    *   Nifedipine XL (Option B): Extended-release nifedipine is too slow in onset (hours) to manage a hypertensive crisis (BP 200/120 mmHg) and is used for maintenance, not acute stabilization. Immediate-release nifedipine would have been a viable option if it were listed, but the extended-release formulation is incorrect.\n    *   Fenoldopam (Option C): While fenoldopam improves renal blood flow and is used in hypertensive emergencies in the general population, data on its use in pregnancy is limited compared to nitroprusside. It is not currently the standard guideline-recommended \"next step\" over nitroprusside for obstetrical hypertensive crisis in major guidelines (ACOG).\n    *   Captopril (Option D): ACE inhibitors are contraindicated in pregnancy (especially 2nd and 3rd trimesters) due to fetal renal toxicity, oligohydramnios, and skull defects.\n    *   Esmolol (Option E): While a short-acting beta-blocker, it does not address the systemic vasoconstriction characteristic of preeclampsia as effectively as a vasodilator and carries a risk of fetal bradycardia. It is not the standard rescue agent for refractory hypertension in this context.\n\nTherefore, despite the risks, sodium nitroprusside is the recognized guideline-based intervention for life-threatening refractory hypertension in pregnancy when first-line agents fail and nicardipine is not an option.\n\nThe answer is (A)"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-003", "question": "A 58-year-old man with metastatic renal cell carcinoma on nivolumab and ipilimumab combination therapy presents with acute respiratory failure requiring mechanical ventilation. Bronchoalveolar lavage shows lymphocytic predominance without infectious organisms. High-dose methylprednisolone (2 mg/kg/day) was initiated 72 hours ago without improvement. Which of the following is the most appropriate next step in management?", "options": ["Add infliximab 5 mg/kg single dose", "Initiate cyclophosphamide 1 g/m² IV", "Switch to dexamethasone 40 mg daily", "Begin plasma exchange therapy", "Add tocilizumab 8 mg/kg IV"], "answer": "A", "answer_index": 0, "explanation": "For steroid-refractory immune checkpoint inhibitor-related pneumonitis, TNF-alpha inhibition with infliximab is the recommended next-line therapy based on retrospective evidence showing improved outcomes. Cyclophosphamide is used for other immune-related adverse events like myocarditis but not first-line for pneumonitis. Switching corticosteroids is unlikely to help if already on high-dose methylprednisolone. Plasma exchange is not established for this condition. Tocilizumab (IL-6 inhibitor) is used for cytokine release syndrome but not specifically for checkpoint inhibitor pneumonitis.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "This patient has severe (Grade 4) immune checkpoint inhibitor (ICI)-associated pneumonitis, evidenced by respiratory failure requiring mechanical ventilation and a bronchoalveolar lavage showing lymphocytic inflammation without infection. The pneumonitis is steroid-refractory, defined as a lack of clinical improvement after 48 to 72 hours of high-dose corticosteroids (methylprednisolone 2 mg/kg/day).\n\nAccording to major clinical practice guidelines (such as those from ASCO, NCCN, SITC, and ESMO) for the management of ICI-related toxicities, the appropriate next step for steroid-refractory pneumonitis is the addition of a second immunosuppressive agent.\n\nThe recommended second-line agents typically include infliximab (a TNF-alpha inhibitor), mycophenolate mofetil (MMF), or intravenous immunoglobulin (IVIG).\n\n*   Infliximab (Option A) is widely cited in guidelines as a primary option for steroid-refractory pneumonitis (dose 5 mg/kg). It has a rapid onset of action favored in acute situations.\n*   Cyclophosphamide (Option B) is generally reserved as a third-line agent for cases that are refractory to both steroids and blocking antibodies like infliximab/MMF, or for fulminant/life-threatening cases (like myocarditis) where other agents have failed.\n*   Switching to dexamethasone (Option C) is unlikely to be effective if the patient is already refractory to high-dose methylprednisolone.\n*   Plasma exchange (Option D) is primarily used for ICI-associated neurological toxicities (e.g., Guillain-Barré syndrome, myasthenia gravis) or sometimes severe renal/myocardial involvement, but not routinely for pneumonitis.\n*   Tocilizumab (Option E) (IL-6 receptor antagonist) is gaining attention and is mentioned in some guidelines as an alternative (often later line or if there are contraindications to TNF blockers), but infliximab remains the more standard guideline-endorsed first choice for additional immunosuppression in this setting.\n\nTherefore, the most appropriate next step according to standard treatment algorithms is to add infliximab.\n\nThe answer is (A)"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-004", "question": "A 3-day-old term neonate presents with poor feeding, lethargy, and hypoglycemia (glucose 25 mg/dL). Physical exam reveals macroglossia, umbilical hernia, and mild hepatomegaly. Newborn screening shows elevated galactose and galactitol. Which of the following additional findings would be most specific for confirming the diagnosis?", "options": ["Elevated serum ammonia level", "Absent reducing substances in urine after lactose challenge", "Normal glycogen content on liver biopsy", "Deficient activity of galactose-1-phosphate uridyltransferase in erythrocytes", "Presence of cataract on ophthalmologic examination"], "answer": "C", "answer_index": 2, "explanation": "The presentation suggests galactosemia, but the key distinguishing feature is that in galactose epimerase deficiency (a rare form), liver biopsy shows normal glycogen content, whereas in classic galactosemia (GALT deficiency), glycogen is depleted. Elevated ammonia suggests urea cycle defect. Absent reducing substances would argue against galactosemia. GALT enzyme deficiency confirms classic galactosemia, not the epimerase variant. Cataracts occur in both forms and are not specific.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "This patient is a 3-day-old neonate presenting with signs of a metabolic crisis: poor feeding, lethargy, hypoglycemia (25 mg/dL), and hepatomegaly. The newborn screening results show elevated galactose and galactitol, which is the key diagnostic feature in this vignette.\n\n1.  Interpretation of Metabolic Findings:\n    *   Elevated Galactose: Indicates an inability to metabolize galactose, which comes from lactose in breast milk or formula.\n    *   Elevated Galactitol: Galactose is converted to galactitol by the enzyme aldose reductase when galactose levels are high. High levels of galactitol are a hallmark of galactosemia.\n    *   Hypoglycemia: In Classic Galactosemia (Galactose-1-phosphate uridyltransferase or GALT deficiency), accumulated Galactose-1-phosphate inhibits phosphoglucomutase and glycogen phosphorylase, preventing glycogen breakdown and causing hypoglycemia. The sequestration of inorganic phosphate also contributes.\n    *   Hepatomegaly: Caused by fat accumulation and toxic injury to the liver from accumulated metabolites.\n\n2.  Physical Exam Distractors:\n    *   The mention of \"macroglossia and umbilical hernia\" combined with hypoglycemia and hepatomegaly is classically associated with Beckwith-Wiedemann Syndrome (BWS) or Congenital Hypothyroidism.\n    *   However, neither BWS nor Hypothyroidism causes elevated galactose and galactitol.\n    *   Congenital Hypothyroidism shares features like lethargy, poor feeding, macroglossia, and umbilical hernia, but the metabolic profile here points definitively to a defect in the galactose pathway. The physical findings might be due to severe metabolic illness (edema/ascites appearing as hernia/swollen tissues) or serve as distractors to test the prioritization of specific biochemical data over general physical signs.\n\n3.  Diagnosis:\n    *   The combination of hypergalactosemia, hypergalactitol, and severe systemic symptoms (hepatomegaly, hypoglycemia, lethargy) strongly suggests Classic Galactosemia (deficiency of GALT).\n    *   Galactokinase (GALK) deficiency typically presents with cataracts and elevated galactose/galactitol but *excess* systemic symptoms like severe hypoglycemia and liver enlargement are not characteristic.\n\n4.  Evaluating the Options:\n    *   A. Elevated serum ammonia: Seen in urea cycle disorders or liver failure, but not specific or diagnostic for galactosemia.\n    *   B. Absent reducing substances in urine: Incorrect. In galactosemia, urine would be positive for reducing substances (galactose) but negative for glucose (on dipstick) if serum glucose is low.\n    *   C. Normal glycogen content on liver biopsy: Not a diagnostic test for galactosemia; used for Glycogen Storage Diseases.\n    *   D. Deficient activity of galactose-1-phosphate uridyltransferase in erythrocytes: This is the gold standard diagnostic test to confirm Classic Galactosemia. It directly identifies the enzymatic defect responsible for the clinical and laboratory findings.\n    *   E. Presence of cataract: While cataracts (oil-drop) are a classic feature of galactosemia due to galactitol accumulation, they may not be present this early (3 days) or are not as specific as the enzymatic assay (cataracts can occur in Rubella, GALK deficiency, Lowe syndrome, etc.).\n\nThe answer is (D)"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-005", "question": "A 42-year-old woman with systemic lupus erythematosus and antiphospholipid syndrome on warfarin (INR 2.5-3.5) presents with acute right leg pain and swelling. Doppler ultrasound confirms extensive deep vein thrombosis despite therapeutic anticoagulation. Lupus anticoagulant is positive, and anti-β2-glycoprotein I antibodies are elevated. Which of the following management strategies is most appropriate?", "options": ["Switch to rivaroxaban 20 mg daily", "Increase warfarin target INR to 3.5-4.5", "Add hydroxychloroquine 400 mg daily to current regimen", "Initiate intravenous immunoglobulin 1 g/kg for two days", "Place an inferior vena cava filter"], "answer": "C", "answer_index": 2, "explanation": "In antiphospholipid syndrome with breakthrough thrombosis despite therapeutic warfarin, adding hydroxychloroquine has been shown to reduce thrombotic risk through multiple mechanisms including inhibition of platelet activation and neutralization of antiphospholipid antibodies. Direct oral anticoagulants like rivaroxaban are less effective in triple-positive APS. Higher INR targets increase bleeding risk without proven benefit. IVIG is reserved for catastrophic APS. IVC filters do not address the hypercoagulable state and increase long-term DVT risk.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This patient has extensive deep vein thrombosis (DVT) while on therapeutic warfarin (INR 2.5-3.5), representing a failure of anticoagulation (recurrent thrombosis) in the setting of high-risk Antiphospholipid Syndrome (APS) and SLE.\n\n1.  Evaluate anticoagulation failture: The first step in management of recurrent thrombosis on warfarin is to assess adherence and ensure the INR was truly therapeutic. The vignette states she was on therapeutic anticoagulation.\n2.  Management options for failure: Guidelines (such as EULAR and ISTH) recommend two main strategies for patients who experience recurrent venous thrombosis despite treatment with Vitamin K Antagonists (VKA) at a target INR of 2.0-3.0 (or higher):\n    *   Switch to Low Molecular Weight Heparin (LMWH).\n    *   Increase the target INR (typically to INR 3.0-4.0).\n3.  Analysis of Options:\n    *   A. Switch to rivaroxaban: Direct Oral Anticoagulants (DOACs) are generally not recommended in patients with APS, especially those with triple-positive profiles or history of arterial thrombosis, and particularly in those who have failed warfarin. The TRAPS trial showed increased risk of thromboembolic events with rivaroxaban compared to warfarin in high-risk APS patients.\n    *   B. Increase warfarin target INR to 3.5-4.5: Since the patient failed treatment with an INR target of 2.5-3.5, escalation of anticoagulation intensity is required. In the absence of an option to switch to LMWH (which is often favored), increasing the INR target is the standard alternative. While guidelines often cite 3.0-4.0, a target of 3.5-4.5 represents the necessary intensification from her baseline of 2.5-3.5 in the context of this exam question.\n    *   C. Add hydroxychloroquine: While hydroxychloroquine is recommended for all patients with SLE and has antithrombotic properties adjunctive to anticoagulation in APS, it is not the primary management strategy for an *acute* breakthrough thrombotic event. It requires time to be effective and does not provide the immediate potent anticoagulation needed for DVT treatment.\n    *   D. Intravenous immunoglobulin: IVIG is used for Catastrophic APS (CAPS) or severe thrombocytopenia, not for uncomplicated recurrent DVT.\n    *   E. Place an inferior vena cava filter: An IVC filter is indicated if there is a contraindication to anticoagulation or recurrent Pulmonary Embolism despite adequate anticoagulation. It does not treat the DVT itself and carries long-term risks.\n\nTherefore, intensifying the warfarin regimen is the most appropriate listed management strategy for handling the anticoagulant failure.\n\nThe answer is (B)"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-006", "question": "A 67-year-old man with ischemic cardiomyopathy (LVEF 25%) and cardiac resynchronization therapy defibrillator presents with recurrent appropriate shocks for ventricular tachycardia. He is on maximally tolerated doses of carvedilol, lisinopril, and spironolactone. Amiodarone was started but discontinued due to thyroid toxicity. Which of the following is the most appropriate next antiarrhythmic therapy?", "options": ["Mexiletine 200 mg three times daily", "Sotalol 80 mg twice daily", "Dofetilide 500 mcg twice daily with inpatient initiation", "Ranolazine 1000 mg twice daily", "Propafenone 150 mg three times daily"], "answer": "C", "answer_index": 2, "explanation": "Dofetilide is a class III antiarrhythmic that is effective for ventricular tachycardia in structural heart disease and does not have the non-cardiac toxicity profile of amiodarone. It requires inpatient initiation due to risk of torsades de pointes. Mexiletine has limited efficacy as monotherapy. Sotalol is contraindicated in severe systolic dysfunction. Ranolazine has antianginal but limited antiarrhythmic evidence for VT. Propafenone is contraindicated in structural heart disease due to proarrhythmic risk.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "This patient has ischemic cardiomyopathy with severe left ventricular dysfunction (LVEF 25%) and is experiencing recurrent ventricular tachycardia (VT) despite guideline-directed medical therapy (including maximally tolerated beta-blockers) and prior amiodarone use (discontinued due to toxicity).\n\n1.  Propafenone (Option E): As a Class IC antiarrhythmic agent, propafenone is absolutely contraindicated in patients with structural heart disease, particularly ischemic heart disease and prior myocardial infarction, due to the increased risk of mortality (proarrhythmia) demonstrated in the CAST trial.\n2.  Sotalol (Option B): Sotalol is a Class III antiarrhythmic with significant beta-blocking properties. While effective for VT, its use in patients with severe heart failure (LVEF 25%) is limited by its negative inotropic effects, which can worsen heart failure. Furthermore, the patient is already on carvedilol, a beta-blocker with proven mortality benefit in HFrEF. Using sotalol would generally require discontinuing carvedilol, thereby removing the mortality benefit associated with carvedilol/metoprolol/bisoprolol in favor of an antiarrhythmic which does not improve survival. Thus, it is not the best choice in this specific context.\n3.  Dofetilide (Option C): Dofetilide is a Class III agent that is safe to use in patients with heart failure and reduced ejection fraction (neutral mortality in the DIAMOND-CHF trial). However, it is primarily indicated and effective for atrial fibrillation and atrial flutter. It has not been shown to be effective for the suppression of ventricular tachycardia in clinical trials.\n4.  Ranolazine (Option D): While Ranolazine (a late sodium channel blocker) has shown some promise in reducing VT burden and ICD shocks (RAID trial), it is generally considered a second-line or add-on therapy and is less established than mexiletine for this indication in standard algorithms.\n5.  Mexiletine (Option A): Mexiletine is a Class IB antiarrhythmic (conceptually an oral analog of lidocaine). It is effective in suppressing ventricular arrhythmias associated with ischemia. Importantly, it does not possess significant negative inotropic properties and is considered safe for use in patients with heart failure. Guidelines and clinical practice support the addition of mexiletine to beta-blocker therapy for the management of recurrent VT in patients with ischemic cardiomyopathy, especially when amiodarone is ineffective or not tolerated. The combination of a beta-blocker and mexiletine often acts synergistically to suppress VT.\n\nTherefore, Mexiletine is the most appropriate next antiarrhythmic therapy.\n\nThe answer is (A)"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-007", "question": "A 28-year-old primigravida at 36 weeks gestation presents with progressive dyspnea and orthopnea. Echocardiography shows peripartum cardiomyopathy with LVEF 30%. After diuresis with furosemide, she remains symptomatic. Which of the following medications should be avoided until after delivery?", "options": ["Digoxin 0.125 mg daily", "Hydralazine 25 mg three times daily", "Isosorbide dinitrate 20 mg three times daily", "Sacubitril/valsartan 24/26 mg twice daily", "Metoprolol succinate 25 mg daily"], "answer": "D", "answer_index": 3, "explanation": "Sacubitril/valsartan contains an ARB (valsartan) which is contraindicated in pregnancy due to fetal renal toxicity and oligohydramnios risk, particularly in the third trimester. Digoxin, hydralazine, isosorbide dinitrate, and metoprolol are all acceptable in pregnancy for heart failure management. While ACE inhibitors and ARBs are absolutely contraindicated, the other medications listed can be used with appropriate monitoring.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "Here is a breakdown of the medication options in the context of pregnancy:\n\n*   A. Digoxin: Digoxin is widely considered safe for use during pregnancy for the treatment of maternal heart failure and fetal tachyarrhythmias. It crosses the placenta but has not been associated with significant teratogenicity.\n*   B. Hydralazine: This is a vasodilator commonly used in pregnancy for the management of hypertension (specifically preeclampsia). In the setting of heart failure with reduced ejection fraction (HFrEF) during pregnancy, the combination of hydralazine and nitrates is the preferred substitute for ACE inhibitors/ARBs to reduce afterload.\n*   C. Isosorbide dinitrate: Nitrates are generally acceptable for use in pregnancy when indicated. As noted above, the combination with hydralazine is the standard of care for afterload reduction in pregnant patients with HFrEF.\n*   D. Sacubitril/valsartan: This medication is an Angiotensin Receptor-Neprilysin Inhibitor (ARNI). It contains Valsartan, an Angiotensin II Receptor Blocker (ARB). Drugs that act directly on the renin-angiotensin system (ACE inhibitors, ARBs, ARNIs) are contraindicated in pregnancy, particularly in the second and third trimesters. They can cause injury and death to the developing fetus, including oligohydramnios, renal failure, pulmonary hypoplasia, and skeletal deformities. This medication must be avoided until after delivery.\n*   E. Metoprolol succinate: Beta-blockers are a cornerstone of heart failure management. While there is a risk of intrauterine growth restriction (IUGR) and neonatal bradycardia/hypoglycemia, beta-1 selective blockers like metoprolol are commonly used in pregnant patients with cardiac conditions because the maternal benefit (and secondary fetal benefit of maternal stability) outweighs the risks.\n\nThe answer is (D)"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-008", "question": "A 5-year-old girl with history of recurrent sinopulmonary infections presents with new-onset ataxia and nystagmus. MRI brain shows diffuse cerebellar atrophy. Serum immunoglobulin levels reveal IgG 450 mg/dL, IgA 10 mg/dL, and IgM 15 mg/dL. Flow cytometry shows absent B cells. Which of the following genetic mutations is most likely responsible for this clinical presentation?", "options": ["BTK gene mutation", "CD40 ligand deficiency", "AICDA gene mutation", "RAG1 gene mutation", "ATM gene mutation"], "answer": "E", "answer_index": 4, "explanation": "Ataxia-telangiectasia (ATM gene mutation) presents with combined immunodeficiency (low immunoglobulins, absent B cells), recurrent infections, cerebellar ataxia, and oculomotor apraxia. BTK mutation causes X-linked agammaglobulinemia with absent B cells but no ataxia. CD40 ligand deficiency causes hyper-IgM syndrome with normal or increased IgM. AICDA mutation causes hyper-IgM syndrome type 2. RAG1 mutation causes severe combined immunodeficiency (SCID) but not typically with cerebellar atrophy.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "E", "model_outputs": "This patient is a 5-year-old girl presenting with cerebellar ataxia (gait instability), nystagmus, and cerebellar atrophy on MRI. She also has a history of recurrent sinopulmonary infections. Her labs show pan-hypogammaglobulinemia and absent B cells.\n\n1.  Analyze the Neurological Findings: The triad of progressive cerebellar ataxia, nystagmus, and cerebellar atrophy in a young child is the hallmark of Ataxia-Telangiectasia (A-T). While oculocutaneous telangiectasias are a classic sign, they often appear later than the ataxia (typically after age 3-6).\n2.  Analyze the Immunodeficiency: A-T is a combined immunodeficiency caused by a defect in DNA repair (specifically double-strand break repair). The ATM gene product is a kinase that orchestrates the DNA damage response.\n    *   This DNA repair mechanism is crucial for V(D)J recombination during lymphocyte development (T and B cell maturation) and class-switch recombination.\n    *   Consequently, patients with A-T often exhibit low levels of immunoglobulins (classically IgA and IgG2, but can be pan-hypogammaglobulinemia) and lymphopenia (affecting both T and B cells). While \"absent B cells\" is the classic textbook description for X-linked Agammaglobulinemia (XLA), the severity of the V(D)J recombination defect in A-T can lead to significant B-cell lymphopenia and hypogammaglobulinemia.\n3.  Evaluate Other Options:\n    *   A. BTK gene mutation: Causes X-linked Agammaglobulinemia (Bruton's). This affects males (X-linked). While it causes absent B cells and sinopulmonary infections, it does not cause limited cerebellar atrophy/ataxia.\n    *   B. CD40 ligand deficiency: Causes X-linked Hyper-IgM syndrome. Affects males. Characterized by elevated/normal IgM and low IgG/IgA. B cells are present (normal CD19 count) but cannot class switch. No cerebellar features.\n    *   C. AICDA gene mutation: Causes Autosomal Recessive Hyper-IgM syndrome. Characterized by elevated IgM. No cerebellar features.\n    *   D. RAG1 gene mutation: Causes SCID (Severe Combined Immunodeficiency) or Omenn syndrome. Typically presents in infancy with severe life-threatening infections and failure to thrive. While it causes absent B and T cells, it does not typically present as new-onset ataxia in a 5-year-old.\n    *   E. ATM gene mutation: Causes Ataxia-Telangiectasia. Fits the age, the specific neurological phenotype (ataxia, cerebellar atrophy), and the immunodeficiency profile (recurrent infections due to defects in lymphocyte development).\n\nThe presence of cerebellar ataxia and atrophy is the most specific discriminating feature in this vignette, pointing directly to a diagnosis of Ataxia-Telangiectasia.\n\nThe answer is (E)"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-009", "question": "A 55-year-old man with alcoholic cirrhosis presents with hepatic encephalopathy refractory to lactulose and rifaximin. He has recurrent episodes requiring hospitalization every 2-3 weeks. Transjugular intrahepatic portosystemic shunt (TIPS) is not an option due to severe pulmonary hypertension. Which of the following interventions has the strongest evidence for reducing recurrent hepatic encephalopathy in this patient?", "options": ["Daily polyethylene glycol 3350 17 g", "Empirical vancomycin 125 mg four times daily", "Oral L-ornithine L-aspartate 6 g three times daily", "Sodium benzoate 5 g twice daily", "Branch-chain amino acid supplementation three times daily"], "answer": "A", "answer_index": 0, "explanation": "Polyethylene glycol has been shown in randomized trials to be more effective than lactulose for acute hepatic encephalopathy and may reduce recurrence by more effectively clearing ammonia-producing bacteria from the gut. Vancomycin has similar efficacy to rifaximin but risk of resistance. L-ornithine L-aspartate has modest benefit as adjunct only. Sodium benzoate is second-line. Branch-chain amino acids improve nutrition but not specifically encephalopathy recurrence.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "E", "model_outputs": "This patient has recurrent hepatic encephalopathy (HE) despite optimal standard therapy (lactulose and rifaximin) and is not a candidate for TIPS due to pulmonary hypertension. This clinical scenario describes refractory HE.\n\nAccording to major clinical practice guidelines (such as AASLD and EASL), when patients are non-responsive to conventional therapy (lactulose and rifaximin), additional agents or alternative strategies should be considered.\n\n1.  Branch-chain amino acids (BCAA): Patients with cirrhosis typically have low levels of BCAAs and high levels of aromatic amino acids (AAA), promoting entry of AAAs into the brain and false neurotransmitter synthesis. Providing oral BCAA supplementation improves nitrogen metabolism and muscle mass. AASLD and EASL guidelines specifically recommend oral BCAAs as an alternative or adjunctive therapy for patients who are not responsive to conventional therapy. Several randomized controlled trials and meta-analyses support their benefit in improving manifestations of HE and quality of life in this population.\n2.  Polyethylene glycol (PEG): While PEG has been shown to be superior to lactulose for the rapid resolution of *acute* HE (HELP trial), evidence for its long-term use in reducing *recurrent* HE in patients already refractory to lactulose is not as established as BCAAs.\n3.  L-ornithine L-aspartate (LOLA): While LOLA can lower ammonia levels, the evidence for oral LOLA in preventing recurrence is mixed, and AASLD guidelines have historically not recommended it as strongly as BCAAs for this indication, whereas EASL suggests it can be considered but prioritizes BCAAs for non-responders.\n4.  Sodium benzoate: This is an alternative ammonia scavenger but is generally considered a second-line or alternative agent when lactulose cannot be taken. It imposes a high sodium load, which is undesirable in cirrhotic patients with ascites.\n5.  Vancomycin: While an effective antibiotic for HE, it is generally reserved for patients intolerant or resistant to rifaximin/lactulose or in specific study settings. Long-term use is limited by concerns regarding renal toxicity and the development of vancomycin-resistant enterococci (VRE). It does not have the same level of guideline endorsement for widespread use in refractory cases as BCAAs do.\n\nTherefore, among the provided options, Branch-chain amino acid supplementation is the most appropriate evidence-based intervention for a patient refractory to standard medical therapy.\n\nThe answer is (E)"}, {"quiz_id": "20251205T084024622Z_deepseek-v3.2_seed126", "question_id": "20251205T084024622Z_deepseek-v3.2_seed126-010", "question": "A 34-year-old woman with metastatic HER2-positive breast cancer on trastuzumab, pertuzumab, and docetaxel presents with acute decompensated heart failure. Echocardiography shows global hypokinesis with LVEF 20%, markedly reduced from baseline 55%. Which of the following biomarkers would be most specific for differentiating trastuzumab-induced cardiomyopathy from anthracycline-like toxicity?", "options": ["Elevated serum troponin I with normal NT-proBNP", "Markedly elevated NT-proBNP with normal troponin", "Elevated soluble ST2 with normal galectin-3", "Increased urinary 8-hydroxy-2'-deoxyguanosine", "Elevated growth differentiation factor-15 (GDF-15)"], "answer": "A", "answer_index": 0, "explanation": "Trastuzumab-induced cardiotoxicity typically presents with elevated troponin (indicating myocyte injury) but relatively preserved NT-proBNP (less volume overload/stretch), reflecting its mechanism of reversible HER2 receptor blockade without direct cellular damage. Anthracycline toxicity shows both elevated troponin and markedly elevated NT-proBNP due to irreversible cellular damage. ST2 and galectin-3 are fibrosis markers not specific to this distinction. 8-OHdG is oxidative stress marker. GDF-15 is elevated in various cardiac conditions.", "generator_model": "deepseek-v3.2", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This question addresses the distinction between Type I (anthracycline-like) and Type II (trastuzumab-like) chemotherapy-related cardiac dysfunction (CRCD).\n\n1.  Pathophysiology:\n    *   Type I (Anthracyclines): Involves oxidative stress leading to cardiomyocyte necrosis and apoptosis. This structural damage is cumulative, dose-related, and often irreversible. Because cell death occurs, serum troponin levels (markers of myocyte injury/necrosis) are typically elevated, particularly during or shortly after administration.\n    *   Type II (Trastuzumab): Involves blockage of HER2 signaling (neuregulin pathway) necessary for myocyte repair and homeostasis, leading to myocardial dysfunction (stunning/hibernation) without overt cell death or structural destruction. This is generally not dose-related and is often reversible upon cessation of the drug. Because there is typically no significant necrosis, serum troponin levels usually remain normal (or are disproportionately low compared to the degree of dysfunction).\n\n2.  Clinical Presentation:\n    *   The patient has acute decompensated heart failure with an LVEF of 20%. In any patient with significant heart failure and wall stress, NT-proBNP (or BNP) will be markedly elevated.\n\n3.  Evaluating the Options:\n    *   A. Elevated serum troponin I with normal NT-proBNP: Normal NT-proBNP is inconsistent with acute decompensated heart failure and LVEF 20%. Elevated troponin would suggest Type I toxicity or ischemia.\n    *   B. Markedly elevated NT-proBNP with normal troponin: This fits the profile of Trastuzumab-induced cardiomyopathy. The high NT-proBNP reflects the hemodynamic stress and failure (LVEF 20%), while the normal troponin indicates the lack of myocyte necrosis, distinguishing it from the necrotic injury seen in anthracycline toxicity.\n    *   C, D, E: While oxidative stress markers (like 8-OHdG) might be elevated in anthracycline toxicity, they are not standard clinical discriminators in this context. ST2 and GDF-15 are prognostic markers but do not specifically differentiate the mechanism (necrosis vs. dysfunction) as clearly as the Troponin/BNP profile in the context of CRCD classification guidelines (e.g., Ewer and Lippman classification).\n\nTherefore, the presence of significant cardiac dysfunction (high NT-proBNP) in the absence of myocyte necrosis (normal troponin) is the hallmark that differentiates trastuzumab toxicity from anthracycline toxicity.\n\nThe answer is (B)"}]